Morgan Stanley Downgrades Merck (MRK) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- Wall Street ends higher as Amazon soothes AI jitters
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
BMO Capital Downgrades Merck (MRK) to Market Perform
May 8, 2014 6:49 AM EDTBMO Capital downgraded Merck (NYSE: MRK) from Outperform to Market Perform with a price target of $60.00 (from $63.00).
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $55.84 yesterday.
... MoreMoody's Sees the Sale of Merck's (MRK) Consumer Products Business as Credit-Positive Move
May 6, 2014 11:40 AM EDTMoody's Investors Service commented that the $14.2 billion sale of Merck & Co., Inc.'s (NYSE: MRK) consumer products business to Bayer AG is credit positive for Merck. There is no impact on Merck's ratings, which include the A1 senior unsecured long-term rating (on guaranteed... More
Merck (MRK) Shares Trade Lower After Co. Gives Corporate and Pipeline Update
May 6, 2014 11:13 AM EDTMerck (NYSE: MRK), known as MSD outside the United States and Canada, today is hosting an Investor Briefing at the companys research facility in Boston. The briefing is also available via webcast at www.merck.com starting at 9:00 a.m. EDT.
Members of the companys senior management team provided updates on the progress Merck has made on its multi-year, strategic initiative to sharpen its commercial and research and development (R&D) focus, bolster its innovative pipeline and accelerate efforts to redesign its operating model and reduce its cost base.
New, Focused... More
